Booz: Pharma should take individual approach to emerging markets

03/28/2013 | PharmaTimes (U.K.)

A new analysis from consultant Booz & Co. notes that emerging markets may not be as lucrative for pharmaceutical companies as they hope. While pharma companies that enter these markets early can help shape them, the report noted that the size of countries classified as "emerging markets" varies, and the "ambitious targets" of some companies have not be met. "Companies should be aware that whilst there is huge potential here, variations within the emerging markets themselves require different and tailored approaches," the report cautions.

View Full Article in:

PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Project Manager RA - 15000003MD
Abbott
Santa Clara, CA
Director, Site Quality Management
CareFusion
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
CT
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC